Vogenx ^{Filed, US Offering, Nasdaq: VOGX}

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, through clinical development and towards regulatory approval. Our lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. We have completed two Phase 2 clinical studies for mizagliflozin in patients diagnosed with PBH, in which a statistically significant reduction in postprandial glucose absorption and insulin secretion, as well as an improvement in both glucose nadir and glucose peak, was observed in the patients dosed with mizagliflozin versus those dosed with placebo or compared to baseline.